Author

Mary E. Hesdorffer

Observed names: M Hesdorffer, M. E. Hesdorffer, M. E. Hesdorrfer, M. Hesdorffer, ME Hesdorffer, Mary Hesdorffer

Institution: Mesothelioma Applied Research Foundation

Observed institutions: MedStar Washington Hospital Center, American Society of Clinical Oncology, Maimonides Medical Center, Memorial Sloan Kettering Cancer Center, Hyogo Medical University, University of California, San Francisco, Columbia University Irving Medical Center, Mesothelioma Applied Research Foundation, University of Chicago, Istituto Dermopatico dell'Immacolata, National Cancer Institute, University of Hawaii Cancer Center, Takeda (Japan), Columbia University

OpenAlex ID: A5079449321

Germline BAP1 mutations predispose to malignant mesothelioma

2011 · Joseph R Testa, Mitchell Cheung, et al. · Nature Genetics · 1,104

Treatment of Malignant Pleural Mesothelioma: American Society of Clinical Oncology Clinical Practice Guideline

2018 · Hedy L. Kindler, Nofisat Ismaila, et al. · Journal of Clinical Oncology · 430

Inherited predisposition to malignant mesothelioma and overall survival following platinum chemotherapy

2019 · Raffit Hassan, Betsy Morrow, et al. · Proceedings of the National Academy of Sciences · 158

Consensus Report of the 2015 Weinman International Conference on Mesothelioma

2016 · Michele Carbone, Shreya Kanodia, et al. · Journal of Thoracic Oncology · 151

PDF

A Subset of Mesotheliomas With Improved Survival Occurring in Carriers ofBAP1and Other Germline Mutations

2018 · Sandra Pastorino, Yoshie Yoshikawa, et al. · Journal of Clinical Oncology · 146

Current and Future Management of Malignant Mesothelioma: A Consensus Report from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applied Research Foundation

2018 · Anne S. Tsao, O. Wolf Lindwasser, et al. · Journal of Thoracic Oncology · 121

PDF

Germline BAP1 Mutational Landscape of Asbestos-Exposed Malignant Mesothelioma Patients with Family History of Cancer

2016 · Jill A. Ohar, Mitchell Cheung, et al. · Cancer Research · 110

Medical and Surgical Care of Patients With Mesothelioma and Their Relatives Carrying Germline BAP1 Mutations

2022 · Michele Carbone, Harvey I. Pass, et al. · Journal of Thoracic Oncology · 100

PDF

A phase II trial of temozolomide in patients with unresectable or metastatic soft tissue sarcoma

2003 · Susan M. Talbot, Mary Louise Keohan, et al. · Cancer · 95

Combined Genetic and Genealogic Studies Uncover a Large BAP1 Cancer Syndrome Kindred Tracing Back Nine Generations to a Common Ancestor from the 1700s

2015 · Michele Carbone, Erin G. Flores, et al. · PLoS Genetics · 93

PDF

The Use of Radiation Therapy for the Treatment of Malignant Pleural Mesothelioma: Expert Opinion from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applied Research Foundation

2019 · Daniel R. Gomez, Andreas Rimner, et al. · Journal of Thoracic Oncology · 76

PDF

The frequent expression of cancer/testis antigens provides opportunities for immunotherapeutic targeting of sarcoma.

2004 · Maha Ayyoub, Robert N Taub, et al. · PubMed · 75

P16 Loss and Mitotic Activity Predict Poor Survival in Patients with Peritoneal Malignant Mesothelioma

2005 · Alain C. Borczuk, Robert N. Taub, et al. · Clinical Cancer Research · 66

Management of Malignant Peritoneal Mesothelioma Using Cytoreductive Surgery and Perioperative Chemotherapy

2016 · Paul H. Sugarbaker, Kiran K. Turaga, et al. · Journal of Oncology Practice · 60

Combined Resection, Intraperitoneal Chemotherapy, and Whole Abdominal Radiation for the Treatment of Malignant Peritoneal Mesothelioma

2008 · Mary E. Hesdorffer, John A. Chabot, et al. · American Journal of Clinical Oncology · 54

Changing Pattern in Malignant Mesothelioma Survival

2015 · Jennifer Faig, Suzanne Howard, et al. · Translational Oncology · 50

PDF

Molecular profiling of malignant peritoneal mesothelioma identifies the ubiquitin–proteasome pathway as a therapeutic target in poor prognosis tumors

2006 · A C Borczuk, G C A Cappellini, et al. · Oncogene · 48

Peritoneal Mesothelioma

2008 · Mary E. Hesdorffer, John Chabot, et al. · Current Treatment Options in Oncology · 43

Radiologic Considerations and Standardization of Malignant Pleural Mesothelioma Imaging Within Clinical Trials: Consensus Statement from the NCI Thoracic Malignancy Steering Committee – International Association for the Study of Lung Cancer – Mesothelioma Applied Research Foundation Clinical Trials Planning Meeting

2019 · Ritu R. Gill, Anne S. Tsao, et al. · Journal of Thoracic Oncology · 24

PDF

Cancer-Related Anxiety

2017 · Gleneara E. Bates, Jadmin L. Mostel, et al. · JAMA Oncology · 24

Two-stage operative cytoreduction and intraperitoneal chemotherapy for diffuse malignant peritoneal mesothelioma: Operative morbidity and mortality in phase I and II trials

2010 · M.D. Kluger, R.N. Taub, et al. · European Journal of Surgical Oncology · 24

Phase II Study of Temozolomide and Thalidomide in Patients with Unresectable or Metastatic Leiomyosarcoma

2008 · Michelle S. Boyar, Mary Hesdorffer, et al. · Sarcoma · 19

PDF

Workshop summary: Potential usefulness and feasibility of a US National Mesothelioma Registry

2019 · Kristin J. Cummings, Michael J. Becich, et al. · American Journal of Industrial Medicine · 16

Pathologic Considerations and Standardization in Mesothelioma Clinical Trials

2019 · Ming-Sound Tsao, Michele Carbone, et al. · Journal of Thoracic Oncology · 15

Inherited predisposition to malignant mesothelioma (MM) due to mutations in DNA repair genes.

2018 · Raffit Hassan, Betsy Morrow, et al. · Journal of Clinical Oncology · 10

Works count: 64

Citation count: 3,150

H-index: 21

I10-index: 25